<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Mol Clin Oncol</journal-id><journal-id journal-id-type="iso-abbrev">Mol Clin Oncol</journal-id><journal-id journal-id-type="publisher-id">MCO</journal-id><journal-title-group><journal-title>Molecular and Clinical Oncology</journal-title></journal-title-group><issn pub-type="ppub">2049-9450</issn><issn pub-type="epub">2049-9469</issn><publisher><publisher-name>D.A. Spandidos</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">28101354</article-id><article-id pub-id-type="pmc">5228213</article-id><article-id pub-id-type="doi">10.3892/mco.2016.1065</article-id><article-id pub-id-type="publisher-id">MCO-0-0-1065</article-id><article-categories><subj-group subj-group-type="heading"><subject>Articles</subject></subj-group></article-categories><title-group><article-title>Histological complete response in a patient with advanced biliary tract cancer treated by gemcitabine/cisplatin/S-1 combination chemotherapy: A case report</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Matsubara</surname><given-names>Tokuhiro</given-names></name><xref ref-type="aff" rid="af1-mco-0-0-1065">1</xref><xref rid="c1-mco-0-0-1065" ref-type="corresp"/></contrib><contrib contrib-type="author"><name><surname>Nishida</surname><given-names>Tsutomu</given-names></name><xref ref-type="aff" rid="af1-mco-0-0-1065">1</xref></contrib><contrib contrib-type="author"><name><surname>Tomimaru</surname><given-names>Yoshito</given-names></name><xref ref-type="aff" rid="af2-mco-0-0-1065">2</xref></contrib><contrib contrib-type="author"><name><surname>Yamamoto</surname><given-names>Masashi</given-names></name><xref ref-type="aff" rid="af1-mco-0-0-1065">1</xref></contrib><contrib contrib-type="author"><name><surname>Hayashi</surname><given-names>Shiro</given-names></name><xref ref-type="aff" rid="af1-mco-0-0-1065">1</xref></contrib><contrib contrib-type="author"><name><surname>Nakajima</surname><given-names>Sachiko</given-names></name><xref ref-type="aff" rid="af1-mco-0-0-1065">1</xref></contrib><contrib contrib-type="author"><name><surname>Fukui</surname><given-names>Koji</given-names></name><xref ref-type="aff" rid="af1-mco-0-0-1065">1</xref></contrib><contrib contrib-type="author"><name><surname>Dono</surname><given-names>Keizo</given-names></name><xref ref-type="aff" rid="af2-mco-0-0-1065">2</xref></contrib><contrib contrib-type="author"><name><surname>Adachi</surname><given-names>Shiro</given-names></name><xref ref-type="aff" rid="af3-mco-0-0-1065">3</xref></contrib><contrib contrib-type="author"><name><surname>Ioka</surname><given-names>Tatsuya</given-names></name><xref ref-type="aff" rid="af4-mco-0-0-1065">4</xref></contrib><contrib contrib-type="author"><name><surname>Kanai</surname><given-names>Masashi</given-names></name><xref ref-type="aff" rid="af5-mco-0-0-1065">5</xref></contrib><contrib contrib-type="author"><name><surname>Inada</surname><given-names>Masami</given-names></name><xref ref-type="aff" rid="af1-mco-0-0-1065">1</xref></contrib></contrib-group><aff id="af1-mco-0-0-1065"><label>1</label>Department of Gastroenterology, Toyonaka Municipal Hospital, Toyonaka, Osaka 560-8565, Japan</aff><aff id="af2-mco-0-0-1065"><label>2</label>Department of Surgery, Toyonaka Municipal Hospital, Toyonaka, Osaka 560-8565, Japan</aff><aff id="af3-mco-0-0-1065"><label>3</label>Department of Pathology, Toyonaka Municipal Hospital, Toyonaka, Osaka 560-8565, Japan</aff><aff id="af4-mco-0-0-1065"><label>4</label>Department of Hepatobiliary and Pancreatic Oncology, Osaka Medical Center for Cancer and Cardiovascular Diseases, Osaka 537-0025, Japan</aff><aff id="af5-mco-0-0-1065"><label>5</label>Department of Clinical Oncology and Pharmacogenomics, Kyoto University Hospital, Kyoto 606-8507, Japan</aff><author-notes><corresp id="c1-mco-0-0-1065"><italic>Correspondence to</italic>: Dr Tokuhiro Matsubara, Department of Gastroenterology, Toyonaka Municipal Hospital, 4-14-1 Shibahara, Toyonaka, Osaka 560-8565, Japan, E-mail: <email>tmatsubara@chp.toyonaka.osaka.jp</email></corresp></author-notes><pub-date pub-type="ppub"><month>12</month><year>2016</year></pub-date><pub-date pub-type="epub"><day>26</day><month>10</month><year>2016</year></pub-date><pub-date pub-type="pmc-release"><day>26</day><month>10</month><year>2016</year></pub-date><!-- PMC Release delay is 0 months and 0 days and was based on the <pub-date pub-type="epub"/>. --><volume>5</volume><issue>6</issue><fpage>757</fpage><lpage>761</lpage><history><date date-type="received"><day>23</day><month>8</month><year>2016</year></date><date date-type="accepted"><day>13</day><month>10</month><year>2016</year></date></history><permissions><copyright-statement>Copyright: &#x000a9; Matsubara et al.</copyright-statement><copyright-year>2016</copyright-year><license license-type="open-access"><license-p>This is an open access article distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">Creative Commons Attribution-NonCommercial-NoDerivs License</ext-link>, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.</license-p></license></permissions><abstract><p>A 68-year-old woman was referred to our hospital with increased levels of biliary enzymes. On imaging, the patient was diagnosed with unresectable intrahepatic biliary tract cancer (BTC) with invasion of the portal vein and para-aortic lymph node metastasis (cT3N1M1, cStage IVb) and underwent endoscopic biliary drainage for the biliary stricture prior to therapy. The patient was subsequently enrolled in a phase III randomized trial (UMIN000014371/NCT02182778) and randomly assigned to receive gemcitabine/cisplatin/S-1 (GCS) combination therapy intravenously at doses of 1,000 or 25 mg/m<sup>2</sup> on day 1 and orally twice daily at a dose of 80 mg/m<sup>2</sup> on days 1&#x02013;7 every 2 weeks. After 12 cycles of scheduled therapy without uncontrollable adverse effects, the patient achieved a good partial response with chemotherapy. Computed tomography (CT) revealed a marked reduction of the primary and metastatic lesions. In addition,<sup>18</sup>F-fluorodeoxyglucose-positron emission tomography/CT revealed diminishing abnormal uptake and no macroscopic evidence of factors adversely affecting tumor resectability. Therefore, the patient underwent extended right hepatic lobectomy, lymph node dissection and left hepaticojejunostomy. Finally, histological examination of the resected tissues revealed no residual cancer cells, suggesting a pathologically complete response. We herein present the case of a patient with intrahepatic BTC who achieved a pathologically complete response following combination chemotherapy with GCS.</p></abstract><kwd-group><kwd>biliary tract cancer</kwd><kwd>cholangiocarcinoma</kwd><kwd>gemcitabine</kwd><kwd>cisplatin</kwd><kwd>S-1</kwd></kwd-group></article-meta></front><body><sec sec-type="intro"><title>Introduction</title><p>Biliary tract cancer (BTC) is a relatively uncommon type of cancer. However, the incidence of BTC appears to be increasing worldwide over the last few decades, particularly in Latin America and East Asia (<xref rid="b1-mco-0-0-1065" ref-type="bibr">1</xref>). BTC is currently the sixth leading cause of cancer-related mortality in Japan, and patients with BTC have a poor prognosis (<xref rid="b2-mco-0-0-1065" ref-type="bibr">2</xref>). Therefore, effective treatment strategies are urgently required. Surgical resection currently represents the only potentially curative treatment for BTC. However, the majority of patients are diagnosed at an advanced stage, when curative resection is no longer feasible; in addition, even in cases where surgery may be performed, there is a significant likelihood of relapse (<xref rid="b3-mco-0-0-1065" ref-type="bibr">3</xref>). Patients with unresectable or recurrent disease appear to be clinical candidates for systemic chemotherapy (<xref rid="b4-mco-0-0-1065" ref-type="bibr">4</xref>,<xref rid="b5-mco-0-0-1065" ref-type="bibr">5</xref>). After the ABC-02 study reported that gemcitabine/cisplatin (GC) combination therapy significantly prolonged median survival time (MST) from 8.1 to 11.7 months over gemcitabine monotherapy in patients with advanced BTC (<xref rid="b6-mco-0-0-1065" ref-type="bibr">6</xref>), this combination therapy has become the standard treatment for BTC worldwide.</p><p>Recently, Kanai <italic>et al</italic> determined the optimal dose of GC/S-1 (GCS) combination therapy for patients with advanced BTC in a phase I study (<xref rid="b7-mco-0-0-1065" ref-type="bibr">7</xref>) and reported a promising MST of &#x0003e;15 months in a phase II study (<xref rid="b8-mco-0-0-1065" ref-type="bibr">8</xref>). Based on these results, a phase III randomized trial is underway to demonstrate the superiority of GCS therapy compared with GC in patients with unresectable BTC (UMIN000014371/NCT02182778). We herein report the case of a patient with unresectable intrahepatic cholangiocarcinoma (ICC) who underwent conversion surgery and ultimately achieved a pathologically complete response using GCS combination therapy.</p></sec><sec><title>Case report</title><p>A 68-year-old woman was referred to Toyonaka Municipal Hospital with increased levels of biliary enzymes in March, 2015. The patient suffered from hypertension and rheumatoid arthritis, which were controlled with oral medication. A physical examination revealed no abdominal abnormalities, but the laboratory tests revealed abnormal liver function, including an elevated serum alkaline phosphatase level of 839 U/l [upper limit of normal (ULN), 328 U/l), a &#x003b3;-glutamyltranspeptidase level of 324 U/l (ULN, 64 U/l) and an alanine aminotransferase level of 82 U/l (ULN, 40 U/l). Additionally, the serum carcinoembryonic antigen (CEA) and carbohydrate antigen (CA) 19-9 levels were 9.8 ng/ml (ULN, 5.0 ng/ml) and 32,806 U/ml (ULN, 37 U/ml), respectively. Computed tomography (CT) revealed a 3-cm mass in the 1/8 segment of the liver, resulting in dilated bile ducts in both hepatic lobes, enlarged para-aortic and regional lymph nodes, and invasion of the portal vein (PV) (<xref rid="f1-mco-0-0-1065" ref-type="fig">Fig. 1A</xref>). Magnetic resonance imaging (MRI) revealed an intrahepatic mass as a hypointense lesion compared with normal liver tissue in T1-weighted images. T2-weighted images revealed mild hyperintensity compared with the liver parenchyma. Furthermore, diffusion-weighted MRI revealed high signal intensity (<xref rid="f1-mco-0-0-1065" ref-type="fig">Fig. 1B</xref>).</p><p>Positron emission tomography with <sup>18</sup>F-fluoro-D-deoxyglucose (<sup>18</sup>F-FDG PET)/CT revealed abnormal uptake of the primary tumor and para-aortic lymph nodes, with an SUV<sub>max</sub> of 5.8 and 2.5, respectively (<xref rid="f3-mco-0-0-1065" ref-type="fig">Fig. 3A</xref>). On imaging, the patient was diagnosed with unresectable intrahepatic BTC with para-aortic and hilar lymph node metastasis [cT3N1M1, cStage IVb according to the Union for International Cancer Control classification system (<uri xlink:type="simple" xlink:href="http://www.uicc.org/sites/main/files/private/TNM_Classification_of_Malignant_Tumours_Website_15%20MAy2011.pdf">http://www.uicc.org/sites/main/files/private/TNM_Classification_of_Malignant_Tumours_Website_15%20MAy2011.pdf</uri>)].</p><p>Endoscopic retrograde cholangiopancreatography (ERCP) revealed a 2-cm irregular stricture of the hilar bile duct with a lobulated tumor (<xref rid="f2-mco-0-0-1065" ref-type="fig">Fig. 2A</xref>). The brush cytology specimens revealed atypical cells in a three-dimensional cluster and an isolated pattern strongly suggestive of adenocarcinoma (<xref rid="f2-mco-0-0-1065" ref-type="fig">Fig. 2B</xref>). Based on these findings, the patient was diagnosed with unresectable ICC with para-aortic lymph node metastasis and, therefore, systemic chemotherapy was considered.</p><p>The patient underwent endoscopic biliary drainage using plastic stent placement for the biliary stricture prior to therapy. Endobiliary stents (7F 12- and 7-cm at a light angle) were successfully placed through the narrowed lumen at initial ERCP, resulting in successful biliary decompression.</p><p>The patient was subsequently enrolled in a phase III randomized trial (UMIN000014371/NCT02182778) and randomly assigned to receive GCS combination therapy.</p><p>Gemcitabine and cisplatin were administered intravenously at doses of 1,000 or 25 mg/m<sup>2</sup> on day 1, and oral S-1 was administered daily at a dose of 80 mg/m<sup>2</sup> on days 1&#x02013;7 every 2 weeks. The patient received 12 cycles of the regimen for 6 months. On the first day of the 8th cycle, the patient presented with grade 3 malaise after receiving chemotherapy. This adverse effect was, however, manageable and improved within 2 days by fluid replacement therapy. The scheduled treatment was completed in accordance with the protocol without delay. After the scheduled 12 cycles of the regimen, CT revealed a marked reduction of the primary tumor and metastatic lymph nodes. <sup>18</sup>F-FDG-PET/CT also revealed diminished abnormal uptake of the primary lesion and para-aortic lymph nodes (<xref rid="f3-mco-0-0-1065" ref-type="fig">Fig. 3B</xref>). Additionally, the serum CEA and CA19-9 levels decreased to within the normal range (1.5 ng/ml and 11 U/ml, respectively).</p><p>Imaging examination showed no macroscopic evidence of factors rendering the tumor unresectable. The patient achieved a good partial response to GCS therapy and was allowed to undergo conversion surgery. Intraoperative frozen section analysis of the lymph nodes showed no malignant findings. Therefore, the patient underwent extended right hepatic lobectomy, lymph node dissection and left hepaticojejunostomy. Macroscopically, curative resection was achieved.</p><p>The resected specimen exhibited almost complete occlusion of the right hepatic duct immediately before the junction (<xref rid="f4-mco-0-0-1065" ref-type="fig">Fig. 4</xref>). The hepatic parenchyma was eroded and replaced by fibrotic tissue. Histological examination revealed scattered pigmented macrophages in the fibrotic tissue, suggesting that necrotic cells were scavenged from this location. Although atypical epithelia in the bile duct were identified, invasive carcinoma and intraepithelial carcinoma components were not found, even following thorough examination. There were no viable carcinoma cells in the dissected nodes, but some contained fibrotic foci (<xref rid="f5-mco-0-0-1065" ref-type="fig">Fig. 5</xref>).</p><p>In summary, a patient with unresectable ICC at presentation achieved a pathologically complete response after undergoing preoperative GCS combination chemotherapy. At the last follow-up, 9 months after the operation (September, 2016), the patient remained alive and recurrence-free, without adjuvant therapy.</p></sec><sec sec-type="discussion"><title>Discussion</title><p>BTC, which originates in the intrahepatic and extrahepatic bile ducts, is a relatively uncommon type of cancer, comprising ~3% of all gastrointestinal malignancies (<xref rid="b9-mco-0-0-1065" ref-type="bibr">9</xref>,<xref rid="b10-mco-0-0-1065" ref-type="bibr">10</xref>). The majority of BTC patients are diagnosed at an advanced stage due to the lack of abdominal symptoms, and the prognosis is generally poor (<xref rid="b1-mco-0-0-1065" ref-type="bibr">1</xref>,<xref rid="b2-mco-0-0-1065" ref-type="bibr">2</xref>). Therefore, surgery is the optimal therapeutic approach, although systemic chemotherapy is considered for patients with unresectable BTC. In the ABC-02 study, Valle <italic>et al</italic> reported that GC combination therapy was associated with a significant survival advantage compared with gemcitabine alone, with a overall MST of 11.7 months compared with 8.1 months, respectively (hazard ratio = 0.64; P&#x0003c;0.001) (<xref rid="b6-mco-0-0-1065" ref-type="bibr">6</xref>). Based on that study, GC combination therapy has been the standard palliative chemotherapy for patients with advanced BTC worldwide. The BT-22 study used the same regimen as the ABC-02 study and evaluated the efficacy and safety for patients with advanced BTC in a Japanese population; the study revealed that its outcome was similar to that of the ABC-02 study, as the MST for GC combination therapy and G alone was 11.2 and 7.7 months, respectively, and the adverse events did not significantly differ between the two groups, although the incidence of hematotoxicity was higher with GC combination therapy compared with G alone (GC vs. G: Leukopenia, 29.3 vs. 19.0%; neutropenia, 56.1 vs. 38.1%; thrombocytopenia, 39.0 vs. 7.2%; and decreased hemoglobin level, 36.6 vs. 16.6%, respectively) (<xref rid="b11-mco-0-0-1065" ref-type="bibr">11</xref>). Therefore, this indicates that the new regimen exhibited a higher efficacy and fewer adverse events.</p><p>S-1 is an oral fluoropyrimidine prodrug that is widely used for various solid tumors (<xref rid="b12-mco-0-0-1065" ref-type="bibr">12</xref>&#x02013;<xref rid="b15-mco-0-0-1065" ref-type="bibr">15</xref>), and it is approved in Japan as a chemotherapeutic agent for BTC (<xref rid="b16-mco-0-0-1065" ref-type="bibr">16</xref>). S-1 monotherapy has shown promising outcomes associated with mild toxicity in BTC patients (<xref rid="b13-mco-0-0-1065" ref-type="bibr">13</xref>). Additionally, in combination with gemcitabine, S-1 has also achieved favorable response rates (30&#x02013;34%) and MST (11.6&#x02013;12.7 months) (<xref rid="b14-mco-0-0-1065" ref-type="bibr">14</xref>,<xref rid="b15-mco-0-0-1065" ref-type="bibr">15</xref>).</p><p>On the basis of these reports, Kanai <italic>et al</italic> expected that the addition of S-1 would exert an additive or synergistic effect with GC combination therapy to improve treatment results with respect to efficacy and safety. In a phase I study, the regimen described below had the fewest grade 3&#x02013;4 adverse events (maculopapular rash, vasovagal reaction and anemia). Based on the incidental rates of adverse events in the phase I study, Kanai <italic>et al</italic> established a recommended dose of the GCS combination therapy, which consisted of intravenous administration of gemcitabine (1,000 mg/m<sup>2</sup>) and cisplatin (25 mg/m<sup>2</sup>) on day 1 and oral administration of S-1 (80 mg/m<sup>2</sup>) on days 1&#x02013;7, every 2 weeks (<xref rid="b7-mco-0-0-1065" ref-type="bibr">7</xref>). Next, the authors evaluated the efficacy of the GCS regimen. A phase II study demonstrated significantly prolonged MST (16.2 months, 95% confidence interval 10.2&#x02013;22.2 months) without uncontrollable adverse events compared with that of the ABC-02 study (11.7 months, hazard ratio = 0.64; P&#x0003c;0.001). Interestingly, two patients (4%) were able to achieve curative secondary resection after tumor downstaging following chemotherapy (<xref rid="b8-mco-0-0-1065" ref-type="bibr">8</xref>). Thus, GCS combination therapy should not only be considered to be a standard first-line chemotherapy, but also a &#x02018;conversion surgery or neoadjuvant chemotherapy&#x02019;. On the basis of these findings, a randomized phase III study has now been launched (UMIN000014371/NCT02182778).</p><p>Conversion surgery is radical resection performed for previously unresectable cases that become resectable as a result of regression following chemotherapy; it should be distinguished from neoadjuvant chemotherapy, although a strict distinction between these two strategies is occasionally clinically difficult, as the definition of unresectable cancer varies among physicians. Conversion surgery or neoadjuvant chemotherapy for unresectable cancers, including gastric, colorectal and pancreatic cancer, has been frequently reported (<xref rid="b17-mco-0-0-1065" ref-type="bibr">17</xref>&#x02013;<xref rid="b19-mco-0-0-1065" ref-type="bibr">19</xref>). Kim <italic>et al</italic> demonstrated that clinically curative conversion therapy resulted in the highest survival rate and best prognosis in gastric cancer patients with peritoneal seeding (cStage IV). The MST of patients undergoing clinically curative conversion therapy and non-curative resection was 37 and 18 months, respectively, and the 3-year survival rates were 50 and 0%, respectively (<xref rid="b17-mco-0-0-1065" ref-type="bibr">17</xref>). For colorectal and pancreatic cancer, several recent reports also demonstrated a clinical advantage with neoadjuvant chemotherapy (<xref rid="b18-mco-0-0-1065" ref-type="bibr">18</xref>,<xref rid="b19-mco-0-0-1065" ref-type="bibr">19</xref>). However, the feasibility and efficacy of neoadjuvant chemotherapy for BTC has not been determined (<xref rid="b20-mco-0-0-1065" ref-type="bibr">20</xref>). Kato <italic>et al</italic> reported that patients with initially unresectable locally advanced BTC who underwent neoadjuvant chemotherapy (gemcitabine) had a significantly longer survival time compared with those unable to undergo surgery (2-year overall survival rate of 45 and 19%, respectively) (<xref rid="b21-mco-0-0-1065" ref-type="bibr">21</xref>). Furthermore, a case of curative resection after GCS chemotherapy for initially unresectable biliary duct cancer and a case of a patient with extrahepatic cholangiocarcinoma after undergoing preoperative gemcitabine-based chemotherapy have been reported (<xref rid="b22-mco-0-0-1065" ref-type="bibr">22</xref>). Based on these reports, conversion therapy has recently attracted attention, although there is insufficient evidence regarding the safety and efficacy of performing conversion surgery. To the best of our knowledge, the present case is the first report of a patient diagnosed with unresectable BTC who ultimately achieved a pathologically complete response with GCS combination therapy. Further studies are required to verify the efficacy of conversion surgery in patients with BTC using a prospective study design.</p></sec></body><back><ack><title>Acknowledgements</title><p>We would like to thank the American Journal Expert copy editing company for the linguistic revision of the manuscript.</p></ack><ref-list><title>References</title><ref id="b1-mco-0-0-1065"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Randi</surname><given-names>G</given-names></name><name><surname>Malvezzi</surname><given-names>M</given-names></name><name><surname>Levi</surname><given-names>F</given-names></name><etal/></person-group><article-title>Epidemiology of biliary tract cancers: an update</article-title><source>Ann Oncol</source><volume>20</volume><fpage>146</fpage><lpage>159</lpage><year>2009</year><pub-id pub-id-type="doi">10.1093/annonc/mdn533</pub-id><pub-id pub-id-type="pmid">18667395</pub-id></element-citation></ref><ref id="b2-mco-0-0-1065"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Matsuda</surname><given-names>T</given-names></name><name><surname>Marugame</surname><given-names>T</given-names></name></person-group><article-title>International comparisons of cumulative risk of gallbladder cancer and other biliary tract cancer, from Cancer Incidence in Five Continents Vol. VIII</article-title><source>Jpn J Clin Oncol</source><volume>37</volume><fpage>74</fpage><lpage>75</lpage><year>2007</year><pub-id pub-id-type="doi">10.1093/jjco/hyl158</pub-id><pub-id pub-id-type="pmid">17272323</pub-id></element-citation></ref><ref id="b3-mco-0-0-1065"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Leonard</surname><given-names>GD</given-names></name><name><surname>O'Reilly</surname><given-names>EM</given-names></name></person-group><article-title>Biliary tract cancers: Current concepts and controversies</article-title><source>Expert Opin Pharmacother</source><volume>6</volume><fpage>211</fpage><lpage>223</lpage><year>2005</year><pub-id pub-id-type="doi">10.1517/14656566.6.2.211</pub-id><pub-id pub-id-type="pmid">15757418</pub-id></element-citation></ref><ref id="b4-mco-0-0-1065"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Glimelius</surname><given-names>B</given-names></name><name><surname>Hoffman</surname><given-names>K</given-names></name><name><surname>Sjoden</surname><given-names>PO</given-names></name><etal/></person-group><article-title>Chemotherapy improves survival and quality of life in advanced pancreatic and biliary cancer</article-title><source>Ann Oncol</source><volume>7</volume><fpage>593</fpage><lpage>600</lpage><year>1996</year><pub-id pub-id-type="doi">10.1093/oxfordjournals.annonc.a010676</pub-id><pub-id pub-id-type="pmid">8879373</pub-id></element-citation></ref><ref id="b5-mco-0-0-1065"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Eckel</surname><given-names>F</given-names></name><name><surname>Schmid</surname><given-names>RM</given-names></name></person-group><article-title>Chemotherapy in advanced biliary tract carcinoma: A pooled analysis of clinical trials</article-title><source>Br J Cancer</source><volume>96</volume><fpage>896</fpage><lpage>902</lpage><year>2007</year><pub-id pub-id-type="doi">10.1038/sj.bjc.6603648</pub-id><pub-id pub-id-type="pmid">17325704</pub-id></element-citation></ref><ref id="b6-mco-0-0-1065"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Valle</surname><given-names>J</given-names></name><name><surname>Wasan</surname><given-names>H</given-names></name><name><surname>Palmer</surname><given-names>DH</given-names></name><name><surname>Cunningham</surname><given-names>D</given-names></name><name><surname>Anthoney</surname><given-names>A</given-names></name><name><surname>Maraveyas</surname><given-names>A</given-names></name><name><surname>Madhusudan</surname><given-names>S</given-names></name><name><surname>Iveson</surname><given-names>T</given-names></name><name><surname>Hughes</surname><given-names>S</given-names></name><name><surname>Pereira</surname><given-names>SP</given-names></name><etal/></person-group><article-title>ABC-02 Trial Investigators: Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer</article-title><source>N Engl J Med</source><volume>362</volume><fpage>1273</fpage><lpage>1281</lpage><year>2010</year><pub-id pub-id-type="doi">10.1056/NEJMoa0908721</pub-id><pub-id pub-id-type="pmid">20375404</pub-id></element-citation></ref><ref id="b7-mco-0-0-1065"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kanai</surname><given-names>M</given-names></name><name><surname>Hatano</surname><given-names>E</given-names></name><name><surname>Kobayashi</surname><given-names>S</given-names></name><name><surname>Fujiwara</surname><given-names>Y</given-names></name><name><surname>Sakai</surname><given-names>D</given-names></name><name><surname>Kodama</surname><given-names>Y</given-names></name><name><surname>Ajiki</surname><given-names>T</given-names></name><name><surname>Nagano</surname><given-names>H</given-names></name><name><surname>Ioka</surname><given-names>T</given-names></name></person-group><article-title>Phase I trial of oral S-1 combined with gemcitabine and cisplatin for advanced biliary tract cancer (KHBO1002)</article-title><source>Cancer Chemother Pharmacol</source><volume>69</volume><fpage>1181</fpage><lpage>1188</lpage><year>2012</year><pub-id pub-id-type="doi">10.1007/s00280-011-1818-2</pub-id><pub-id pub-id-type="pmid">22237958</pub-id></element-citation></ref><ref id="b8-mco-0-0-1065"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kanai</surname><given-names>M</given-names></name><name><surname>Hatano</surname><given-names>E</given-names></name><name><surname>Kobayashi</surname><given-names>S</given-names></name><name><surname>Fujiwara</surname><given-names>Y</given-names></name><name><surname>Marubashi</surname><given-names>S</given-names></name><name><surname>Miyamoto</surname><given-names>A</given-names></name><name><surname>Shiomi</surname><given-names>H</given-names></name><name><surname>Kubo</surname><given-names>S</given-names></name><name><surname>Ikuta</surname><given-names>S</given-names></name><name><surname>Yanagimoto</surname><given-names>H</given-names></name><etal/></person-group><article-title>A multi-institution phase II study of gemcitabine/cisplatin/S-1 (GCS) combination chemotherapy for patients with advanced biliary tract cancer (KHBO 1002)</article-title><source>Cancer Chemother Pharmacol</source><volume>75</volume><fpage>293</fpage><lpage>300</lpage><year>2015</year><pub-id pub-id-type="doi">10.1007/s00280-014-2648-9</pub-id><pub-id pub-id-type="pmid">25477010</pub-id></element-citation></ref><ref id="b9-mco-0-0-1065"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sia</surname><given-names>D</given-names></name><name><surname>Tovar</surname><given-names>V</given-names></name><name><surname>Moeini</surname><given-names>A</given-names></name><name><surname>Llovet</surname><given-names>JM</given-names></name></person-group><article-title>Intrahepatic cholangiocarcinoma: Pathogenesis and rationale for molecular therapies</article-title><source>Oncogene</source><volume>32</volume><fpage>4861</fpage><lpage>4870</lpage><year>2013</year><pub-id pub-id-type="doi">10.1038/onc.2012.617</pub-id><pub-id pub-id-type="pmid">23318457</pub-id></element-citation></ref><ref id="b10-mco-0-0-1065"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vauthey</surname><given-names>JN</given-names></name><name><surname>Blumgart</surname><given-names>LH</given-names></name></person-group><article-title>Recent advances in the management of cholangiocarcinomas</article-title><source>Semin Liver Dis</source><volume>14</volume><fpage>109</fpage><lpage>114</lpage><year>1994</year><pub-id pub-id-type="doi">10.1055/s-2007-1007302</pub-id><pub-id pub-id-type="pmid">8047893</pub-id></element-citation></ref><ref id="b11-mco-0-0-1065"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Okusaka</surname><given-names>T</given-names></name><name><surname>Nakachi</surname><given-names>K</given-names></name><name><surname>Fukutomi</surname><given-names>A</given-names></name><name><surname>Mizuno</surname><given-names>N</given-names></name><name><surname>Ohkawa</surname><given-names>S</given-names></name><name><surname>Funakoshi</surname><given-names>A</given-names></name><name><surname>Nagino</surname><given-names>M</given-names></name><name><surname>Kondo</surname><given-names>S</given-names></name><name><surname>Nagaoka</surname><given-names>S</given-names></name><name><surname>Funai</surname><given-names>J</given-names></name><etal/></person-group><article-title>Gemcitabine alone or in combination with cisplatin in patients with biliary tract cancer: A comparative multicentre study in Japan</article-title><source>Br J Cancer</source><volume>103</volume><fpage>469</fpage><lpage>474</lpage><year>2010</year><pub-id pub-id-type="doi">10.1038/sj.bjc.6605779</pub-id><pub-id pub-id-type="pmid">20628385</pub-id></element-citation></ref><ref id="b12-mco-0-0-1065"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ichinose</surname><given-names>Y</given-names></name><name><surname>Yoshimori</surname><given-names>K</given-names></name><name><surname>Sakai</surname><given-names>H</given-names></name><etal/></person-group><article-title>S-1 plus cisplatin combination chemotherapy in patients with advanced non-small cell lung cancer: a multi-institutional phase II trial</article-title><source>Clinical cancer research: an official journal of the American Association for Cancer Research.</source><volume>10</volume><fpage>7860</fpage><lpage>7864</lpage><year>2004</year><pub-id pub-id-type="doi">10.1158/1078-0432.CCR-04-0143</pub-id><pub-id pub-id-type="pmid">15585618</pub-id></element-citation></ref><ref id="b13-mco-0-0-1065"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Furuse</surname><given-names>J</given-names></name><name><surname>Okusaka</surname><given-names>T</given-names></name><name><surname>Boku</surname><given-names>N</given-names></name><name><surname>Ohkawa</surname><given-names>S</given-names></name><name><surname>Sawaki</surname><given-names>A</given-names></name><name><surname>Masumoto</surname><given-names>T</given-names></name><name><surname>Funakoshi</surname><given-names>A</given-names></name></person-group><article-title>S-1 monotherapy as first-line treatment in patients with advanced biliary tract cancer: A multicenter phase II study</article-title><source>Cancer Chemother Pharmacol</source><volume>62</volume><fpage>849</fpage><lpage>855</lpage><year>2008</year><pub-id pub-id-type="doi">10.1007/s00280-007-0673-7</pub-id><pub-id pub-id-type="pmid">18214482</pub-id></element-citation></ref><ref id="b14-mco-0-0-1065"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sasaki</surname><given-names>T</given-names></name><name><surname>Isayama</surname><given-names>H</given-names></name><name><surname>Nakai</surname><given-names>Y</given-names></name><name><surname>Ito</surname><given-names>Y</given-names></name><name><surname>Kogure</surname><given-names>H</given-names></name><name><surname>Togawa</surname><given-names>O</given-names></name><name><surname>Toda</surname><given-names>N</given-names></name><name><surname>Yasuda</surname><given-names>I</given-names></name><name><surname>Hasebe</surname><given-names>O</given-names></name><name><surname>Maetani</surname><given-names>I</given-names></name><etal/></person-group><article-title>Multicenter, phase II study of gemcitabine and S-1 combination chemotherapy in patients with advanced biliary tract cancer</article-title><source>Cancer Chemother Pharmacol</source><volume>65</volume><fpage>1101</fpage><lpage>1107</lpage><year>2010</year><pub-id pub-id-type="doi">10.1007/s00280-009-1115-5</pub-id><pub-id pub-id-type="pmid">19707761</pub-id></element-citation></ref><ref id="b15-mco-0-0-1065"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kanai</surname><given-names>M</given-names></name><name><surname>Yoshimura</surname><given-names>K</given-names></name><name><surname>Tsumura</surname><given-names>T</given-names></name><name><surname>Asada</surname><given-names>M</given-names></name><name><surname>Suzuki</surname><given-names>C</given-names></name><name><surname>Niimi</surname><given-names>M</given-names></name><name><surname>Matsumoto</surname><given-names>S</given-names></name><name><surname>Nishimura</surname><given-names>T</given-names></name><name><surname>Nitta</surname><given-names>T</given-names></name><name><surname>Yasuchika</surname><given-names>K</given-names></name><etal/></person-group><article-title>A multi-institution phase II study of gemcitabine/S-1 combination chemotherapy for patients with advanced biliary tract cancer</article-title><source>Cancer Chemother Pharmacol</source><volume>67</volume><fpage>1429</fpage><lpage>1434</lpage><year>2011</year><pub-id pub-id-type="doi">10.1007/s00280-010-1443-5</pub-id><pub-id pub-id-type="pmid">20811895</pub-id></element-citation></ref><ref id="b16-mco-0-0-1065"><label>16</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sasaki</surname><given-names>T</given-names></name><name><surname>Isayama</surname><given-names>H</given-names></name><name><surname>Nakai</surname><given-names>Y</given-names></name><name><surname>Mizuno</surname><given-names>S</given-names></name><name><surname>Yamamoto</surname><given-names>K</given-names></name><name><surname>Yagioka</surname><given-names>H</given-names></name><name><surname>Yashima</surname><given-names>Y</given-names></name><name><surname>Kawakubo</surname><given-names>K</given-names></name><name><surname>Kogure</surname><given-names>H</given-names></name><name><surname>Togawa</surname><given-names>O</given-names></name><etal/></person-group><article-title>Multicenter phase II study of S-1 monotherapy as second-line chemotherapy for advanced biliary tract cancer refractory to gemcitabine</article-title><source>Invest New Drugs</source><volume>30</volume><fpage>708</fpage><lpage>713</lpage><year>2012</year><pub-id pub-id-type="doi">10.1007/s10637-010-9553-9</pub-id><pub-id pub-id-type="pmid">20924641</pub-id></element-citation></ref><ref id="b17-mco-0-0-1065"><label>17</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kim</surname><given-names>SW</given-names></name></person-group><article-title>The result of conversion surgery in gastric cancer patients with peritoneal seeding</article-title><source>J Gastric Cancer</source><volume>14</volume><fpage>266</fpage><lpage>270</lpage><year>2014</year><pub-id pub-id-type="doi">10.5230/jgc.2014.14.4.266</pub-id><pub-id pub-id-type="pmid">25580359</pub-id></element-citation></ref><ref id="b18-mco-0-0-1065"><label>18</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Adam</surname><given-names>R</given-names></name><name><surname>Wicherts</surname><given-names>DA</given-names></name><name><surname>de Haas</surname><given-names>RJ</given-names></name><name><surname>Ciacio</surname><given-names>O</given-names></name><name><surname>L&#x000e9;vi</surname><given-names>F</given-names></name><name><surname>Paule</surname><given-names>B</given-names></name><name><surname>Ducreux</surname><given-names>M</given-names></name><name><surname>Azoulay</surname><given-names>D</given-names></name><name><surname>Bismuth</surname><given-names>H</given-names></name><name><surname>Castaing</surname><given-names>D</given-names></name></person-group><article-title>Patients with initially unresectable colorectal liver metastases: Is there a possibility of cure?</article-title><source>J Clin Oncol</source><volume>27</volume><fpage>1829</fpage><lpage>1835</lpage><year>2009</year><pub-id pub-id-type="doi">10.1200/JCO.2008.19.9273</pub-id><pub-id pub-id-type="pmid">19273699</pub-id></element-citation></ref><ref id="b19-mco-0-0-1065"><label>19</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Morganti</surname><given-names>AG</given-names></name><name><surname>Massaccesi</surname><given-names>M</given-names></name><name><surname>La Torre</surname><given-names>G</given-names></name><name><surname>Caravatta</surname><given-names>L</given-names></name><name><surname>Piscopo</surname><given-names>A</given-names></name><name><surname>Tambaro</surname><given-names>R</given-names></name><name><surname>Sofo</surname><given-names>L</given-names></name><name><surname>Sallustio</surname><given-names>G</given-names></name><name><surname>Ingrosso</surname><given-names>M</given-names></name><name><surname>Macchia</surname><given-names>G</given-names></name><etal/></person-group><article-title>A systematic review of resectability and survival after concurrent chemoradiation in primarily unresectable pancreatic cancer</article-title><source>Ann Surg Oncol</source><volume>17</volume><fpage>194</fpage><lpage>205</lpage><year>2010</year><pub-id pub-id-type="doi">10.1245/s10434-009-0762-4</pub-id><pub-id pub-id-type="pmid">19856029</pub-id></element-citation></ref><ref id="b20-mco-0-0-1065"><label>20</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Grendar</surname><given-names>J</given-names></name><name><surname>Grendarova</surname><given-names>P</given-names></name><name><surname>Sinha</surname><given-names>R</given-names></name><name><surname>Dixon</surname><given-names>E</given-names></name></person-group><article-title>Neoadjuvant therapy for downstaging of locally advanced hilar cholangiocarcinoma: A systematic review</article-title><source>HPB Oxf</source><volume>16</volume><fpage>297</fpage><lpage>303</lpage><year>2014</year><pub-id pub-id-type="doi">10.1111/hpb.12150</pub-id></element-citation></ref><ref id="b21-mco-0-0-1065"><label>21</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kato</surname><given-names>A</given-names></name><name><surname>Shimizu</surname><given-names>H</given-names></name><name><surname>Ohtsuka</surname><given-names>M</given-names></name><name><surname>Yoshidome</surname><given-names>H</given-names></name><name><surname>Yoshitomi</surname><given-names>H</given-names></name><name><surname>Furukawa</surname><given-names>K</given-names></name><name><surname>Takeuchi</surname><given-names>D</given-names></name><name><surname>Takayashiki</surname><given-names>T</given-names></name><name><surname>Kimura</surname><given-names>F</given-names></name><name><surname>Miyazaki</surname><given-names>M</given-names></name></person-group><article-title>Surgical resection after downsizing chemotherapy for initially unresectable locally advanced biliary tract cancer: A retrospective single-center study</article-title><source>Ann Surg Oncol</source><volume>20</volume><fpage>318</fpage><lpage>324</lpage><year>2013</year><pub-id pub-id-type="doi">10.1245/s10434-012-2312-8</pub-id><pub-id pub-id-type="pmid">23149849</pub-id></element-citation></ref><ref id="b22-mco-0-0-1065"><label>22</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Furukawa</surname><given-names>K</given-names></name><name><surname>Uwagawa</surname><given-names>T</given-names></name><name><surname>Sakamoto</surname><given-names>T</given-names></name><name><surname>Shiba</surname><given-names>H</given-names></name><name><surname>Tsutsumi</surname><given-names>J</given-names></name><name><surname>Yanaga</surname><given-names>K</given-names></name></person-group><article-title>Curative resection after gemcitabine, cisplatin and S-1 chemotherapy for initially unresectable biliary duct cancer: A case report</article-title><source>Anticancer Res</source><volume>35</volume><fpage>4203</fpage><lpage>4206</lpage><year>2015</year><pub-id pub-id-type="pmid">26124379</pub-id></element-citation></ref></ref-list></back><floats-group><fig id="f1-mco-0-0-1065" orientation="portrait" position="float"><label>Figure 1.</label><caption><p>Imaging of intrahepatic biliary tract cancer. A computed tomography scan revealed a 3-cm mass in the 1/8 segment of the liver, resulting in bile duct dilation in both hepatic lobes, enlarged regional lymph nodes and invasion of the PV: (A) Arrow, intrahepatic mass; (B) arrow, enlarged regional lymph nodes; (C) arrowhead, enlarged para-aortic lymph nodes; (D) arrowhead, invasion of the PV. MRI also revealed the intrahepatic mass: (E) T1-weighted image showing a hypointense lesion (arrow) relative to the normal liver; (F) T2-weighted image showing mild hyperintensity (arrow) relative to the liver parenchyma; (G) diffusion-weighted MRI showing high signal intensity (arrowhead); (H) MRCP revealed irregular stricture of the hilar bile duct (arrowhead). PV, portal vein; MRI, magnetic resonance imaging; MRCP, magnetic resonance cholangiopancreatography.</p></caption><graphic xlink:href="mco-05-06-0757-g00"/></fig><fig id="f2-mco-0-0-1065" orientation="portrait" position="float"><label>Figure 2.</label><caption><p>Irregular stricture of the hilar bile duct with lobulated tumor was observed on endoscopic retrograde cholangiopancreatography (ERCP) and brush cytology. (A) ERCP showing irregular stricture of the hilar bile duct (arrows). (B) A three-dimensional cluster containing atypical cells with considerable variation in nuclear size was observed on brush cytology. The cells exhibited enlarged atypical nuclei with irregular contours and hyperchromasia. Papanicolaou staining identified the cells as class V.</p></caption><graphic xlink:href="mco-05-06-0757-g01"/></fig><fig id="f3-mco-0-0-1065" orientation="portrait" position="float"><label>Figure 3.</label><caption><p><sup>18</sup>F-fluorodeoxyglucose positron emission tomography/computed tomography (<sup>18</sup>F-FDG-PET/CT) of the primary lesion and lymph nodes prior to and following chemotherapy. (A and B) Prior to chemotherapy, <sup>18</sup>F-FDG-PET/CT showed abnormal uptake of the primary tumor (bold arrow) and para-aortic lymph nodes (thin arrow). (C and D) After chemotherapy, <sup>18</sup>F-FDG-PET/CT showed a marked disappearance of the abnormal uptake of the primary lesion (bold arrow) and lymph nodes (thin arrow).</p></caption><graphic xlink:href="mco-05-06-0757-g02"/></fig><fig id="f4-mco-0-0-1065" orientation="portrait" position="float"><label>Figure 4.</label><caption><p>(A) Macroscopically resected specimen and (B) cross sections. The right hepatic duct was almost occluded immediately before the junction (arrows).</p></caption><graphic xlink:href="mco-05-06-0757-g03"/></fig><fig id="f5-mco-0-0-1065" orientation="portrait" position="float"><label>Figure 5.</label><caption><p>Histological complete response demonstrated by histopathological examination. (A) Expanded fibrous tissue around the occluded right hepatic duct. The eroded hepatic parenchyma was replaced by dense collagenous tissue. (B) Although there was an increased number of capillaries as well as various inflammatory cells in the fibrous tissue, no invasive carcinoma cells were identified. (C) High magnification view showing numerous enlarged pigmented macrophages in the fibrous tissue, suggesting the presence of scavenged necrotic carcinoma cells.</p></caption><graphic xlink:href="mco-05-06-0757-g04"/></fig></floats-group></article>